

June 25, 2008

APA DSM-V Work Group Member

Name, Degree: Roberto Lewis-Fernández, M.D.
Role(s) in Work Group: Member, Anxiety, Obsessive-Compulsive Spectrum, Posttraumatic, and Dissociative Disorders Work Group
Institutional Affiliation(s): Columbia Univ., NY State Psychiatric Institute, Harvard Univ.
City, State: New York, NY

Brief Biographical Sketch:

Dr. Roberto Lewis-Fernández is Director of the NYS Cultural Competence Center of Excellence and the Hispanic Treatment Program at New York State Psychiatric Institute, Associate Professor of Clinical Psychiatry at Columbia University, and Lecturer on Social Medicine at Harvard University. He received his B.A. from Harvard College in 1979, a Master’s Degree in comparative religion from Harvard Divinity School in 1982, and his M.D. from Yale Medical School in 1986. He obtained his psychiatric training at The Cambridge Hospital (1986-90) and completed a Dupont-Warren psychiatric research fellowship (1990-91) and an NIMH-sponsored fellowship in clinically applied medical anthropology (1991-93) at Harvard Medical School. From 1993 to 1995, Dr. Lewis-Fernández worked for the Puerto Rico Health Department implementing an innovative mental health consultation-liaison program for rural primary care clinics.

His research focuses on the socio-cultural determinants of illness experience, symptomatology, help-seeking behavior, and treatment outcome among U.S. Latinos diagnosed with anxiety, depressive, and dissociative disorders. Specific interests include the relationship between psychiatric diagnoses and Latino popular syndromes; socio-cultural factors associated with treatment dropout; misdiagnosis of psychosis as a result of folk idioms of distress; symptom presentations of trauma-related disorders among Latino patients; and collaboration models between mental health and primary care medicine to increase access to culturally competent care for consumers with psychiatric disorders.

Dr. Lewis-Fernández was on the DSM-IV Cross-Cultural Committee and the NIMH Study Group on Mental Health Services in Specialty Settings (2002-2007). He is currently the chair of the Cultural Psychiatry Committee of the Group for the Advancement of Psychiatry, a member of the Committee on Psychiatric Diagnosis and Assessment of the American Psychiatric Association, and a member of the Community Services Board of the NYC Department of Health and Mental Hygiene. From 1996 to 2007, he also served as Editor of the Cases Section of *Culture, Medicine and Psychiatry*, which publishes clinical cases illustrating the impact of culture on the symptoms, course, and outcome of psychiatric disorders and patients' help-seeking choices.

UNCOMPENSATED AFFILIATIONS WITH NON-PROFIT OR ADVOCACY ORGANIZATIONS THAT MAY HAVE A DIRECT OR INDIRECT INTEREST IN PSYCHIATRIC DIAGNOSIS, TREATMENT, OR THE DSM-V : CALENDAR YEARS 2005, 2006, 2007, AND FOR 2008, ACTIVITIES TO DATE AND COMMITMENTS FOR REMAINDER OF YEAR.

| Non-Profit and Advocacy Organizations | Year(s) | Role |
|--|----------------|---|
| Group for the Advancement of Psychiatry | 2005-2008 | Chair, Cultural Psychiatry Committee |
| American Psychiatric Association | 2006-2008 | Member, Committee on Psychiatric Diagnosis & Assessment |

The two tables below represent Dr. Lewis-Fernández’s disclosure of significant interests and

affiliations for: (1) The full calendar years of 2005, 2006, and 2007; and (2) for 2008, interests and affiliations to date and commitments for remainder of the year.

Dr. Lewis-Fernández has agreed that, from the time of approval through the publication of DSM-V, projected in 2012, (his/her) aggregate annual income derived from industry sources (excluding unrestricted research grants) will not exceed \$10,000 in any calendar year.

| | |
|---|--|
| <p>KEY NUMBER:</p> <p>1. Consultation Fees (include scientific advisory boards)</p> <p>2. Full- or Part-time Employee</p> <p>3. Industry-related Grant-Research Support received or pending</p> <p>4. Honoraria (includes Speakers' Bureau)</p> <p>5. Stock or other financial options</p> | <p>6. Expert testimony</p> <p>7. Royalties (including right to share of revenue or profit from pharmaceutical, device or other development or product)</p> <p>8. Patents received or pending</p> <p>9. Officer, director/trustee, executive (specify)</p> <p>10. Other (specify)</p> |
|---|--|

DISCLOSURE OF SIGNIFICANT INTERESTS FOR 2005, 2006, AND 2007

| Commercial or Other Organization | Year(s) | Key #(s) |
|--|----------------|-----------------|
| Glaxo Smith Kline | 2005-2007 | 3 |
| Pfizer Corp | 2005 | 3 |
| Continuing Education Wizards (unrestricted educational grant from Eli Lilly) | 2005 | 4 |
| Eli Lilly | 2006-2007 | 3 |
| 13 CME (unrestricted educational grant from AstraZeneca) | 2007 | 4 |
| Welcome Back Awards Committee (supported by Eli Lilly) | 2007 | 4 |

DISCLOSURE OF SIGNIFICANT INTERESTS TO DATE FOR 2008 AND COMMITMENTS FOR REMAINDER OF YEAR

| Commercial or Other Organization | Year(s) | Key #(s) |
|--|----------------|-----------------|
| Glaxo Smith Kline | 2008 | 3 |
| Eli Lilly | 2008 | 3 |
| Welcome Back Awards Committee (supported by Eli Lilly) | 2008 | 4 |